107 related articles for article (PubMed ID: 8157048)
1. Flumazenil kinetics in the elderly.
Roncari G; Timm U; Zell M; Zumbrunnen R; Weber W
Eur J Clin Pharmacol; 1993; 45(6):585-7. PubMed ID: 8157048
[TBL] [Abstract][Full Text] [Related]
2. Flumazenil disposition and elimination in cirrhosis.
Janssen U; Walker S; Maier K; von Gaisberg U; Klotz U
Clin Pharmacol Ther; 1989 Sep; 46(3):317-23. PubMed ID: 2505960
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects.
Rochdi M; Sabouraud A; Girre C; Venet R; Scherrmann JM
Eur J Clin Pharmacol; 1994; 46(4):351-4. PubMed ID: 7957521
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics of submucosal vs. intravenous flumazenil (Romazicon) in an animal model.
Oliver FM; Sweatman TW; Unkel JH; Kahn MA; Randolph MM; Arheart KL; Mandrell TD
Pediatr Dent; 2000; 22(6):489-93. PubMed ID: 11132509
[TBL] [Abstract][Full Text] [Related]
5. Stability and pharmacokinetics of flumazenil in the rat.
Mandema JW; Gubbens-Stibbe JM; Danhof M
Psychopharmacology (Berl); 1991; 103(3):384-7. PubMed ID: 2057540
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration.
Roncari G; Ziegler WH; Guentert TW
Br J Clin Pharmacol; 1986 Oct; 22(4):421-8. PubMed ID: 3094572
[TBL] [Abstract][Full Text] [Related]
7. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine.
Robertson DR; Waller DG; Renwick AG; George CF
Br J Clin Pharmacol; 1988 Mar; 25(3):297-305. PubMed ID: 3358895
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
[TBL] [Abstract][Full Text] [Related]
9. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
Seaber E; On N; Dixon RM; Gibbens M; Leavens WJ; Liptrot J; Chittick G; Posner J; Rolan PE; Pack RW
Br J Clin Pharmacol; 1997 Jun; 43(6):579-87. PubMed ID: 9205817
[TBL] [Abstract][Full Text] [Related]
10. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
[TBL] [Abstract][Full Text] [Related]
11. Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers.
Crevoisier C; Delisle MC; Joseph I; Foletti G
Eur Neurol; 2003; 49(3):173-7. PubMed ID: 12646763
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations.
Göhler K; Brett M; Smit JW; Rengelshausen J; Terlinden R
Int J Clin Pharmacol Ther; 2013 Apr; 51(4):338-48. PubMed ID: 23357834
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E
Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614
[TBL] [Abstract][Full Text] [Related]
14. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
[TBL] [Abstract][Full Text] [Related]
15. Drug interactions and clinical pharmacokinetics of flumazenil.
Klotz U
Eur J Anaesthesiol Suppl; 1988; 2():103-8. PubMed ID: 2842128
[TBL] [Abstract][Full Text] [Related]
16. Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex.
Divoll M; Greenblatt DJ; Ochs HR; Shader RI
Anesth Analg; 1983 Jan; 62(1):1-8. PubMed ID: 6849499
[TBL] [Abstract][Full Text] [Related]
17. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man.
Flesch G; Müller P; Lloyd P
Eur J Clin Pharmacol; 1997; 52(2):115-20. PubMed ID: 9174680
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet.
Schulz HU; Schürer M; Bässler D; Weiser D
Arzneimittelforschung; 2005; 55(1):15-22. PubMed ID: 15727160
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of brotizolam in the elderly.
Jochemsen R; Nandi KL; Corless D; Wesselman JG; Breimer DD
Br J Clin Pharmacol; 1983; 16 Suppl 2(Suppl 2):299S-307S. PubMed ID: 6661375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
